E2F1 and neoplasm: These included activation of the NF-κB (including pathway members NFKB1 and RELA), and E2F (including pathway members E2F1, E2F2 and E2F3) signalling pathways, activation of the stem cell/cancer-associated transcription factor NANOG and activation of the ligand-activated transcription factor AHR. Inhibited TFs included the tumour suppressing p53 and Rb pathways (including pathway members RB1 and CDKN2A (p16)).